PMID- 17261959
OWN - NLM
STAT- MEDLINE
DCOM- 20070327
LR  - 20131121
IS  - 0160-2446 (Print)
IS  - 0160-2446 (Linking)
VI  - 49
IP  - 1
DP  - 2007 Jan
TI  - Impact of simvastatin and losartan on antiinflammatory effect: in vitro study.
PG  - 20-6
AB  - Antiinflammatory properties of losartan are currently unclear. This study tested 
      the hypothesis that losartan itself has an antiinflammatory effect comparable to 
      that of simvastatin. Human umbilical vein endothelial cells (HUVECs) were (1) 
      incubated with culture medium alone, (2) incubated with added C-reactive protein 
      (CRP) (25, 50, 75, and 100 microg/mL) for stimulation, and (3) pretreated with 
      losartan (stepwise increased dose: 100, 300, 500, and 750 micromol/L) and 
      simvastatin (stepwise increased dose: 25, 50, 75, and 100 micromol/L) for 4 hours 
      before adding CRP for stimulation. Surface expression of vascular cell adhesion 
      molecule-1 (VCAM-1) was determined by flow cytometry. Supernatant levels of 
      monocyte chemoattractant protein-1 (MCP-1) and interleukin-6 (IL-6) were measured 
      by ELISA. Experimental results showed that the effect of CRP on VCAM-1 expression 
      and supernatant levels of MCP-1 and IL-6 increases stepwise as CRP concentrations 
      increase from 25 to 50 to 75 to 100 microg/mL (all P < 0.001). The effect of CRP 
      on VCAM-1 expression in HUVECs and supernatant levels of MCP-1 and IL-6 were 
      significantly suppressed by 25 micromol/L simvastatin with stepwise increased 
      suppression as simvastatin dose increased to 50, 75, and 100 micromol/L (all P < 
      0.0001). However, losartan did not significantly suppress CRP's effect on VCAM-1 
      expression in HUVECs (P > 0.5). Moreover, losartan did not suppress CRP's effect 
      on MCP-1 and IL-6 secretion unless a high dose (> or =500 micromol/L) of losartan 
      was used. Compared with simvastatin, losartan had less effect on suppression of 
      CRP-mediated inflammation.
FAU - Chang, Li-Teh
AU  - Chang LT
AD  - Basic Science, Nursing Department, Meiho Institute of Technology, Pingtung, 
      Taiwan, ROC.
FAU - Sun, Cheuk-Kwan
AU  - Sun CK
FAU - Chiang, Chiang-Hua
AU  - Chiang CH
FAU - Wu, Chiung-Jen
AU  - Wu CJ
FAU - Chua, Sarah
AU  - Chua S
FAU - Yip, Hon-Kan
AU  - Yip HK
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Angiotensin II Type 1 Receptor Blockers)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticholesteremic Agents)
RN  - 0 (Receptor, Angiotensin, Type 1)
RN  - 0 (Vascular Cell Adhesion Molecule-1)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - AGG2FN16EV (Simvastatin)
RN  - JMS50MPO89 (Losartan)
SB  - IM
MH  - Angiotensin II Type 1 Receptor Blockers/*pharmacology
MH  - Anti-Inflammatory Agents, Non-Steroidal/*metabolism/pharmacology
MH  - Anticholesteremic Agents/*pharmacology
MH  - C-Reactive Protein/*physiology
MH  - Cells, Cultured
MH  - Endothelial Cells/*drug effects/metabolism/pathology
MH  - Endothelium, Vascular/drug effects/metabolism/pathology
MH  - Humans
MH  - Losartan/*pharmacology
MH  - Receptor, Angiotensin, Type 1/biosynthesis/genetics
MH  - Simvastatin/*pharmacology
MH  - Vascular Cell Adhesion Molecule-1/biosynthesis/drug effects/genetics
EDAT- 2007/01/31 09:00
MHDA- 2007/03/28 09:00
CRDT- 2007/01/31 09:00
PHST- 2007/01/31 09:00 [pubmed]
PHST- 2007/03/28 09:00 [medline]
PHST- 2007/01/31 09:00 [entrez]
AID - 00005344-200701000-00004 [pii]
AID - 10.1097/FJC.0b013e31802ba4ec [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 2007 Jan;49(1):20-6. doi: 10.1097/FJC.0b013e31802ba4ec.